Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Max-40279-01 + Toripalimab in Advanced Solid Tumors
NCT05369286Phase 1Unknown
- Sponsor
- Guangzhou Zaiji Medical Technology
- Start
- Apr 2022
- Primary completion
- May 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of nefextinib in solid tumor (advanced stage) (5 arms), sponsored by Guangzhou Zaiji Medical Technology. Primary endpoints: Dose-Limiting Toxicities at 21 days and Treatment-Emergent Adverse Events at 24 months. Status: unknown.
02
Drugs
nefextinib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05369286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05369286.